ASG-22ME
Showing 1 - 25 of 5,507
Metastatic Urothelial Carcinoma, Urothelial Tumors Trial (Coformulated favezelimab/pembrolizumab, Coformulated
Not yet recruiting
- Metastatic Urothelial Carcinoma
- Urothelial Neoplasms
- Coformulated favezelimab/pembrolizumab
- +3 more
- (no location specified)
Apr 26, 2023
Metastatic Penile Squamous Cell Carcinoma, Stage III Penile Cancer AJCC v8, Stage IV Penile Cancer AJCC v8 Trial in Phoenix,
Not yet recruiting
- Metastatic Penile Squamous Cell Carcinoma
- +3 more
- Enfortumab Vedotin
-
Phoenix, Arizona
- +2 more
Oct 23, 2023
Renal Pelvis and Ureter Urothelial Carcinoma Trial in Los Angeles (procedure, drug, biological)
Not yet recruiting
- Renal Pelvis and Ureter Urothelial Carcinoma
- Biopsy
- +5 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Mar 15, 2023
Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma, Metastatic
Recruiting
- Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation
- +3 more
- Cabozantinib S-malate
- +3 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Aug 8, 2022
Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Tumor Trial in Atlanta (procedure,
Not yet recruiting
- Bladder Squamous Cell Carcinoma
- +10 more
- Biospecimen Collection
- +5 more
-
Atlanta, Georgia
- +3 more
Feb 20, 2023
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter
Recruiting
- Locally Advanced Bladder Urothelial Carcinoma
- +18 more
- Enfortumab Vedotin
- Erdafitinib
-
Los Angeles, California
- +2 more
Jun 28, 2022
Metastatic Urothelial Cancer Trial in China (Enfortumab vedotin)
Active, not recruiting
- Metastatic Urothelial Cancer
- Enfortumab vedotin
-
Beijing, China
- +7 more
Aug 23, 2022
Carcinoma, Transitional Cell, Urinary Bladder Tumors, Urologic Tumors Trial in Worldwide (enfortumab vedotin (EV),
Active, not recruiting
- Carcinoma, Transitional Cell
- +6 more
- enfortumab vedotin (EV)
- +4 more
-
Anchorage, Alaska
- +105 more
Dec 19, 2022
Adults in South Korea With Cancer Who Receive PADCEV Injection
Recruiting
- Urothelial Cancer
- Enfortumab Vedotin
-
Seoul, Korea, Republic ofKR82004
Aug 22, 2023
Metastatic Urothelial Cancer Trial in Japan (Enfortumab vedotin)
Completed
- Metastatic Urothelial Cancer
- Enfortumab vedotin
-
Tsukuba, Ibaraki, Japan
- +7 more
Mar 2, 2020
Anastomotic Leak Rectum Trial in Worldwide (Obsidian ASG)
Recruiting
- Anastomotic Leak Rectum
- Obsidian ASG
-
Graz, Austria
- +14 more
Apr 1, 2022
Neovascular (Wet) Age-related Macular Degeneration (AMD) Trial in United Kingdom (Stereotactic radiotherapy (16 Gray or Sham),
Active, not recruiting
- Neovascular (Wet) Age-related Macular Degeneration (AMD)
- Stereotactic radiotherapy (16 Gray or Sham)
- 0.5 mg ranibizumab
-
Huntingdon, Cambridgeshire, United Kingdom
- +29 more
Apr 1, 2022
Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part
Completed
- Esophageal Squamous Cell Carcinoma
- Nivolumab
-
Truro, Cornwall, United Kingdom
- +35 more
May 18, 2022
Aortic Aneurysm, Thoracic, Pseudoaneurysm, Aortic Dissection Trial (GORE® Ascending Stent Graft (ASG device), GORE® TAG®
Not yet recruiting
- Aortic Aneurysm, Thoracic
- +3 more
- GORE® Ascending Stent Graft (ASG device)
- +2 more
- (no location specified)
Apr 10, 2023
It's Not JUST Idiopathic Pulmonary Fibrosis Study
Recruiting
- Interstitial Lung Disease
- Idiopathic Pulmonary Fibrosis
- Optional Bronchoscopy
- +3 more
-
Burton on Trent, Derbyshire, United Kingdom
- +23 more
Jul 1, 2021
SARS-CoV-2 Infection, COVID-19 Trial in United Kingdom (SARS-CoV-2 rS/Matrix M1-Adjuvant, Placebo, Licensed seasonal influenza
Active, not recruiting
- SARS-CoV-2 Infection
- COVID-19
- SARS-CoV-2 rS/Matrix M1-Adjuvant
- +2 more
-
Belfast, Antrim, United Kingdom
- +32 more
Oct 19, 2022
Intracranial Hemorrhages, Intracranial Hemorrhage, Hypertensive, Subarachnoid Hemorrhage Trial in United Kingdom (Apixaban,
Completed
- Intracranial Hemorrhages
- +8 more
- Apixaban
- +6 more
-
Edinburgh, Midlothian, United Kingdom
- +66 more
Mar 31, 2022
Carcinoma, Renal Cell, Clear-cell Metastatic Renal Cell Carcinoma Trial in Worldwide (Nivolumab/Ipilimumab)
Active, not recruiting
- Carcinoma, Renal Cell
- Clear-cell Metastatic Renal Cell Carcinoma
- Nivolumab/Ipilimumab
-
Linz, Austria
- +34 more
Aug 3, 2021
Transitional Cell Carcinoma, Advanced Cancer, Metastatic Cancer Trial in Austria, Germany (Nivolumab/Ipilimumab)
Active, not recruiting
- Transitional Cell Carcinoma
- +2 more
- Nivolumab/Ipilimumab
-
Graz, Austria
- +26 more
Nov 2, 2021
Locally Advanced or Metastatic Urothelial Carcinoma (UC) Trial in United States (enfortumab vedotin (EV))
Approved for marketing
- Locally Advanced or Metastatic Urothelial Carcinoma (UC)
- enfortumab vedotin (EV)
-
Los Angeles, California
- +14 more
Jan 9, 2020
Pretreated Metastatic Colorectal Cancer Trial in Mainz (TAS 102, Regorafenib)
Completed
- Pretreated Metastatic Colorectal Cancer
- TAS 102
- Regorafenib
-
Mainz, GermanyUniversitätsmedizin Mainz, I.Medizinische Klinik und Poliklinik
Mar 25, 2021
Healthy, Physical Inactivity Trial in Riyadh (therapeutic Exercise)
Completed
- Healthy
- Physical Inactivity
- therapeutic Exercise
-
Riyadh, Saudi ArabiaPrincess Nourah bint Abdulrahman University
May 7, 2023
Impact of Obsidian ® ASG on Anastomotic Healing
Unknown status
- Anastomotic Leak Rectum
- Obsidian ASG®
-
Linz, Upper Austria, AustriaClinic for General and Visceral Surgery, Kepler University Clini
May 8, 2020